-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, USvDev1kYdGodatMzd2YXNuMq1GgCZxFGjvIxl6omowogXEGv1zx/RdhUV2WHp3v q+BTQ55yENmtyIcySx55OQ== 0001104659-11-000902.txt : 20110110 0001104659-11-000902.hdr.sgml : 20110110 20110110090114 ACCESSION NUMBER: 0001104659-11-000902 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110107 ITEM INFORMATION: Other Events FILED AS OF DATE: 20110110 DATE AS OF CHANGE: 20110110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NPS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000890465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 870439579 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23272 FILM NUMBER: 11518934 BUSINESS ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 BUSINESS PHONE: (908) 450-5300 MAIL ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 8-K 1 a11-3017_18k.htm 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

January 7, 2011

Date of Report (Date of earliest event reported)

 

NPS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

0-23272

 

87-0439579

(State or other jurisdiction of

incorporation)

 

(Commission File Number)

 

(I.R.S. Employer

Identification Number)

 

550 Hills Drive, 3rd Floor

Bedminster, NJ 07921

(Address of principal executive offices)

 

(908) 450-5300

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

ITEM 8.01.  Other Events.

 

On January 7, 2011, the United States District Court, District of Delaware ruled in favor of NPS Pharmaceuticals, Inc. (“NPS”), Amgen, Inc. (“Amgen”) and The Brigham and Women’s Hospital (“BWH” and together with NPS and Amgen, the “Plaintiffs”), in their lawsuit against Teva Pharmaceuticals USA, Inc. (“Teva USA”), Teva Pharmaceutical Industries Ltd. (“Teva Israel”, and together with Teva USA, “Teva”) and Barr Laboratories, Inc. (“Barr”).  The Plaintiffs’ lawsuit was based on Abbreviated New Drug Applications, or ANDAs, filed by Teva and Barr which seek approval to market generic versions of Sensipar® (cinacalcet hydrochloride).  The court&# 146;s order enjoined Teva and Barr from the commercial manufacture, use, import, offer for sale, or sale of their generic cinacalcet hydrochloride until the expiration of U.S. Patent Nos. 6,011,068; 6, 031,003 and 6,211,244. U.S. Patent No. 6,011,068 is the last of these patents to expire, which, by virtue of patent term extension, will be on March 8, 2018.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:  January 10, 2011

NPS PHARMACEUTICALS, INC.

 

 

 

By:

/s/ EDWARD STRATEMEIER

 

 

Edward Stratemeier
Senior Vice President, General Counsel and Secretary

 

3

 -----END PRIVACY-ENHANCED MESSAGE-----